ZyVersa Therapeutics Faces Delisting Concerns
Ticker: ZVSA · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
ZyVersa's on the chopping block - might get delisted!
AI Summary
ZyVersa Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company was formerly known as Larkspur Health Acquisition Corp. and changed its name on April 26, 2021. The filing indicates potential issues with maintaining its listing on the stock exchange.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being delisted, significantly impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe indicator of financial or operational trouble, posing a significant risk to investors.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- Larkspur Health Acquisition Corp. (company) — Former company name
- September 14, 2025 (date) — Date of earliest event reported
- September 18, 2025 (date) — Date of report
- April 26, 2021 (date) — Date of name change
- 001-41184 (other) — SEC File Number
FAQ
What is the specific reason for ZyVersa Therapeutics' potential delisting?
The filing is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule or standard not met.
When was the company formerly known as Larkspur Health Acquisition Corp.?
The company changed its name from Larkspur Health Acquisition Corp. on April 26, 2021.
What is the filing date of this 8-K report?
The report was filed on September 18, 2025.
What is ZyVersa Therapeutics' principal executive office address?
The principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
What is the SEC file number for ZyVersa Therapeutics?
The SEC file number is 001-41184.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-18 07:00:46
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZVSA — (1) Indicate by
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-013968.txt ( ) — 200KB
- zvsa-20250914.xsd (EX-101.SCH) — 3KB
- zvsa-20250914_lab.xml (EX-101.LAB) — 33KB
- zvsa-20250914_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2025 ZYVERSA THERAPEUTICS, INC. /s/ Stephen Glover Stephen Glover Chief Executive Officer